Valneva Austria Gmbh
Clinical trials sponsored by Valneva Austria Gmbh, explained in plain language.
Vaccine development subsidiary of Valneva SE.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a single shot shield children from chikungunya?
⭐️ VACCINE ⭐️ CompletedThis trial is testing whether a single injection of an experimental chikungunya vaccine, VLA1553, is safe and triggers a protective immune response in healthy children aged 1 to 11 years. About 300 children will receive either a full dose, a half dose, or a control vaccine. The s…
Phase: PHASE2 • Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Zika vaccine candidate enters human safety testing
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested an inactivated Zika virus vaccine (VLA1601) in 150 healthy adults aged 18-49. Participants received two doses, and researchers monitored side effects and immune responses. The goal was to find the safest and most effective dose, including combination…
Phase: PHASE1 • Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:00 UTC